Patent intelligence · US
US 10941143
Imidazo [1,5-a]pyridine compounds and their use
Imidazo [1,5-a]pyridine compounds and their use
Patent details — US 10941143
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 9, 2021
- Expiration
- Mar 4, 2041
- Applicant
- Alterity Therapeutics Limited
- Claims
- 22
- CPC classes
- A61P, A61P25/16, A61P25/24, A61P25/28
Quick answer
US 10941143 (Imidazo [1,5-a]pyridine compounds and their use) is held by Alterity Therapeutics Limited. Status: granted. Granted Mar 9, 2021. Expires Mar 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Alterity Therapeutics Limited
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61P, A61P25/16, A61P25/24, A61P25/28
More from Alterity Therapeutics Limited
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 10941143?
US 10941143 (Imidazo [1,5-a]pyridine compounds and their use) is held by Alterity Therapeutics Limited. Status: granted. Granted Mar 9, 2021. Expires Mar 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10941143?
Alterity Therapeutics Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 10941143 expire?
Our index shows an expiration date of Mar 4, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.